Generative AI expansion of the Cysteinomix drug discovery platform

Otsuka Holdings' Integrated Report 2026 says technology validation has started to expand the Cysteinomix drug discovery platform using generative AI. In the same report, Taiho Pharmaceutical's Tsukuba discovery division says it is working to introduce robotics and AI in the search for drug targets and compound design while expanding Cysteinomix.